-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
In order to further protect the safety of public medication, the National Medical Products Administration has decided to revise the [Adverse Reactions] and [Precautions] items in the instructions for Gefitinib tablets
1.
If the revised content involves the label of a drug, it shall be revised together; the instructions and other content of the label shall be consistent with the original approved content
Gefitinib tablets manufacturers should conduct in-depth research on the mechanism of new adverse reactions, take effective measures to conduct publicity and training on use and safety issues, and promptly notify drug dealers and users of changes in the content of drug safety in an appropriate manner , Instruct physicians and pharmacists to use drugs rationally
2.
3.
Hereby announce
Attachment: Requirements for revision of the instructions for Gefitinib tablets
State Food and Drug Administration
January 21, 2021